MedTrace Logo

TESTING -ON Post-Trial ObservatioNal Cohort Study

NCT05434325 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 366

Last updated 2025-02-11

No results posted yet for this study

Summary

The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).

Conditions

Sponsors & Collaborators

  • Peking University Institute of Nephrology

    collaborator UNKNOWN

  • The George Institute

    lead OTHER

Principal Investigators

  • Hong Zhang, Prof · Peking University Institute of Nephrology

  • Vlado Perkovic, Prof · University of New South Wales

  • Muh Geot Wong, Dr · University of New Souht Wales

  • Jicheng Lv · Peking University of Nephrology

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-07
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • Australia
  • Canada
  • China
  • Hong Kong
  • India
  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434325 on ClinicalTrials.gov